Evidence map›Paper›PMID 41756325›Full record

ReviewFrontiers in oncology2026

Honey and cancer: from traditional medicine to modern adjuvant therapy.

Abdalsalam Kmail

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Abdalsalam KmailDepartment of Biology & Biotechnology, Faculty of Sciences, Arab American University, Jenin, Palestine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains one of the principal causes of death worldwide, with conventional treatments like chemotherapy and radiotherapy often exhibiting high toxicity, resistance, and relapse rates. These constraints have sparked new investigation of bioactive phytochemicals as complements to standard therapies, in an attempt to increase efficacy and reduce toxicity. Honey, an ancient natural product used in ethnomedicine, has been the focus of recent attention due to its multifactorial biochemical composition and possible anticancer properties. This review aggregates recent research on honey's anticancer activities, describing its molecular mechanisms-including caspase-mediated apoptosis, cell cycle regulation, reduction of NF-κB and STAT3 activity, and metastasis prevention. We review preclinical studies in various cancer models, highlighting honey's ability to sensitize tumors to chemotherapy. Finally, we review clinical data on honey's ability to relieve therapy-induced side effects such as mucositis and hematologic suppression. In spite of promising data, issues remain about standardizing its active components, pharmacokinetics, and lack of large scale human trials. This review supports honey's incorporation into evidence-based oncology paradigms pending additional robust validation.

Indexed as

adjuvant cancer therapyapitherapychemotherapy-induced toxicityhoneymethylglyoxalnatural compounds

Identifiers

PMID41756325
PMCPMC12932228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.